|1.||Citrome, Leslie: 20 articles (10/2014 - 09/2005)|
|2.||Loebel, Antony: 18 articles (06/2015 - 02/2004)|
|3.||Kane, John M: 16 articles (09/2015 - 01/2003)|
|4.||Leucht, Stefan: 16 articles (01/2014 - 04/2007)|
|5.||Rummel-Kluge, Christine: 14 articles (01/2014 - 01/2009)|
|6.||Komossa, Katja: 14 articles (01/2014 - 01/2009)|
|7.||Karayal, Onur N: 13 articles (01/2015 - 06/2009)|
|8.||Harvey, Philip D: 13 articles (04/2011 - 02/2004)|
|9.||Schwarz, Sandra: 12 articles (01/2013 - 01/2009)|
|10.||Hunger, Heike: 12 articles (01/2013 - 01/2009)|
|1.||Schizophrenia (Dementia Praecox)
11/01/2005 - "Ziprasidone is an atypical antipsychotic with a highly specific receptorbinding profile that has been shown to be effective for both positive and negative symptoms of schizophrenia. "
05/01/2002 - "Efficacy data and most safety data for ziprasidone support its use as a first-line treatment for schizophrenia; however, its potential effects on ventricular repolarization relegate it to second-line status in patients with comorbid cardiovascular risks."
10/01/2007 - "This study suggests that ziprasidone may be beneficial for long-term treatment of schizophrenia patients in terms of severity of symptoms, and general functioning. "
08/01/2006 - "This sample was selected because previous findings suggested that clinical and NP symptoms of schizophrenia significantly improved from baseline after a switch to ziprasidone treatment. "
08/01/2013 - "Uncontrolled studies have suggested that increasing the dose of ziprasidone above the standard maximum daily dose of 160 mg may be more effective for some patients with schizophrenia. "
|2.||Bipolar Disorder (Mania)
04/01/2010 - "In this analysis, ziprasidone significantly improved both depressive and manic mood symptoms in patients with dysphoric mania, suggesting that it might be a useful treatment option in this patient population. "
04/01/2010 - "Ziprasidone-treated patients also demonstrated significant improvements on the Mania Rating Scale and all secondary efficacy measures, and had significantly higher response and remission rates compared with placebo. "
11/01/2012 - "Our findings indicate that ziprasidone may be effective in achieving sustained remission in bipolar I disorder and propose that a better understanding regarding the definition of remission in bipolar disorders should be required in clinical practice since our results showed different remission rates with different remission criteria."
06/01/2006 - "Open-label treatment for up to 52 weeks supported the sustained efficacy of ziprasidone in bipolar disorder. "
01/01/2013 - "As anticipated, ziprasidone was found to be effective for its indicated uses, although its utility in mania and mixed states lacked comparative data. "
|3.||Psychotic Disorders (Schizoaffective Disorder)
02/01/2001 - "This study assessed the efficacy of ziprasidone for the treatment of schizoaffective disorder. "
12/01/2011 - "Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile."
07/01/2008 - "In a 24-h, double-blind study, hospitalized patients with psychotic disorder and acute agitation were randomized to treatment with fixed doses of IM ziprasidone: 2 mg (N=38) or 20 mg (N=41). "
07/01/2004 - "The patient was a 15-year-old male adolescent with a history of schizoaffective disorder treated with ziprasidone capsules, 80 mg QD for 8 weeks prior to presentation. "
01/01/2002 - "In addition, intramuscular ziprasidone shows efficacy and good tolerability in the treatment of acute agitation associated with psychotic disorders."
06/01/2012 - "Further studies are needed to elucidate the precise mechanism of lower propensity of weight gain of ziprasidone."
05/01/2007 - "The study showed that ziprasidone was effective and tolerable, that use of ziprasidone was characterized by an absence of extrapyramidal symptoms and weight gain, and that no alterations in clinical laboratory tests occurred. "
01/01/2007 - "The favourable tolerability of ziprasidone has been confirmed in long-term extension studies and its use was not associated with weight gain or dyslipidaemia. "
05/28/2005 - "The aim of this study was to investigate effects of ziprasidone on weight gain and reproductive function in female rats. "
01/01/2001 - "In short- and long-term clinical trials, ziprasidone had a low liability for side-effects typically associated with poor compliance, such as EPS, weight gain and sexual dysfunction. "
|5.||Weight Loss (Weight Reduction)
10/01/2007 - "Ziprasidone had the most benign metabolic profile, and in phase 2T was associated with a higher likelihood of weight loss for patients who gained greater than seven percent of their initial body weight in Phase 1. Treating clinicians need access to all of these medications in order to optimize treatment for the individual patient."
01/01/2015 - "Several reports suggest that weight loss is observed in switching other antipsychotics to ziprasidone. "
01/01/2014 - "Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone."
05/01/2013 - "Ziprasidone hydrochloride monohydrate was heated from 30 to 150° with a heating rate of 5° per min under nitrogen gas atmosphere and weight loss data were collected. "
07/01/2010 - "Protracted, dose-dependent weight loss after addition of ziprasidone to a stable regimen of clozapine."
|2.||Risperidone (Risperdal Consta)
|4.||Antipsychotic Agents (Antipsychotics)
|10.||Valproic Acid (Valproate, Semisodium)
|1.||Drug Therapy (Chemotherapy)
|2.||Hormone Replacement Therapy (Therapy, Hormone Replacement)